-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical professionals read the reference
October has ended, in the past month, what clinical guidelines have been updated to allow doctors to recharge and start again?
Let's take a look at the October must-read guide of the summary of small medicines, and friends who want to get the original text can download the clinical decision-making assistant App to get the original text
for free.
AACE/ACE: Clinical Practice Guidelines for Integrative Care of Diabetes (2022)
This guideline includes 170 up-to-date evidence-based clinical practice recommendations
on integrated care for people with diabetes.
The recommendations are divided into four parts:
(1) screening, diagnosis, blood glucose targeting, and blood glucose monitoring;
(2) comorbidities and complications, including obesity and its management related to lifestyle, nutrition and bariatric surgery, hypertension, dyslipidemia, retinopathy, neuropathy, diabetic nephropathy and cardiovascular disease;
(3) prediabetes, type 2 diabetes drug treatment and management of blood glucose goals, type 1 diabetes combined with insulin therapy, hypoglycemia, hospitalized patients and women with gestational diabetes;
and (4) education and new topics on diabetes and infertility, nutritional supplements, secondary diabetes, social determinants of health, and virtual care, as well as updated recommendations
on cancer risk, non-pharmacological components of pediatric care plans, depression, educational and team approaches, occupational risks, the role of sleep medications, and vaccination for people with diabetes.
This latest clinical practice guideline provides evidence-based, person-centered, team-based clinical decision-making with the aim of improving care for people with diabetes
.
EASD/ADA: Benefits, Challenges, and Recommendations for Automated Insulin Delivery (2022)
Driven by a continuous glucose monitoring system that allows physicians to regulate insulin delivery at insulin pumps based on sensor blood glucose data, regulatory approval of the first automated insulin delivery (AID) is approving by regulators system, which has been applied to
clinical care.
For this automated insulin delivery system, this article lists a range of factors
that regulators, manufacturing companies, international and national professional associations, funding agencies, researchers, health care professionals, and people with diabetes need to carefully consider.
(1) The AID system user guide is more systematic and structured;
(2) improve the consistency and availability of safety reports;
(3) increase investment in the collection of clinical data to support or oppose evidence of the use of AID systems;
(4) increase the availability of confidential and secure use of AID systems for all consumer groups;
(5) Increase communication and cooperation
between stakeholder groups.
The AGA: Guidelines for Clinical Practice of Pharmacological Interventions in Obese Patients in Adults (2022)
guideline group made 9 recommendations
.
The group strongly recommends pharmacological therapy for overweight and obese adults (body mass index ≥ 30 kg/m 2, or ≥ 27 kg/m2 with weight-related complications) who do not have adequate lifestyle interventions.
The panel recommended the use of 2.
4 mg of semaglutide, 3.
0 mg of liraglutide, phentermine-topiramate sustained-release, and naltrexone-bupropion sustained-release (based on moderate-certainty evidence), as well as phentermine and diethylpropionic acid (based on low-certainty evidence) for the long-term management of
overweight and obesity.
The guideline group recommends against orlistat
.
For overweight and obese adults who do not respond adequately to lifestyle interventions alone, long-term pharmacotherapy is recommended, and a variety of effective and safe treatment options
are available.
What are the diagnostic criteria for major diseases? What are the preferred therapeutic drugs and regimens? What clinical signs and symptoms are prioritized for diagnosing a disease?
Open the clinical guideline module of the decision assistant App, and the dialogue with the major guidelines at home and abroad authoritative guidelines decision-making assistant "clinical guidelines
" module has 1 👇.
Scan the QR code below 2.
Download the Clinical Decision Assistant App
3 Open the Decision Assistant app and click the icon
Clinical Decision Assistant App October Guidelines Collection
October has ended, in the past month, what clinical guidelines have been updated to allow doctors to recharge and start again?
Let's take a look at the October must-read guide of the summary of small medicines, and friends who want to get the original text can download the clinical decision-making assistant App to get the original text
for free.
AACE/ACE: Clinical Practice Guidelines for Integrative Care of Diabetes (2022)
This guideline includes 170 up-to-date evidence-based clinical practice recommendations
on integrated care for people with diabetes.
The recommendations are divided into four parts:
(1) screening, diagnosis, blood glucose targeting, and blood glucose monitoring;
(2) comorbidities and complications, including obesity and its management related to lifestyle, nutrition and bariatric surgery, hypertension, dyslipidemia, retinopathy, neuropathy, diabetic nephropathy and cardiovascular disease;
(3) prediabetes, type 2 diabetes drug treatment and management of blood glucose goals, type 1 diabetes combined with insulin therapy, hypoglycemia, hospitalized patients and women with gestational diabetes;
and (4) education and new topics on diabetes and infertility, nutritional supplements, secondary diabetes, social determinants of health, and virtual care, as well as updated recommendations
on cancer risk, non-pharmacological components of pediatric care plans, depression, educational and team approaches, occupational risks, the role of sleep medications, and vaccination for people with diabetes.
This latest clinical practice guideline provides evidence-based, person-centered, team-based clinical decision-making with the aim of improving care for people with diabetes
.
EASD/ADA: Benefits, Challenges, and Recommendations for Automated Insulin Delivery (2022)
Driven by a continuous glucose monitoring system that allows physicians to regulate insulin delivery at insulin pumps based on sensor blood glucose data, regulatory approval of the first automated insulin delivery (AID) is approving by regulators system, which has been applied to
clinical care.
For this automated insulin delivery system, this article lists a range of factors
that regulators, manufacturing companies, international and national professional associations, funding agencies, researchers, health care professionals, and people with diabetes need to carefully consider.
(1) The AID system user guide is more systematic and structured;
(2) improve the consistency and availability of safety reports;
(3) increase investment in the collection of clinical data to support or oppose evidence of the use of AID systems;
(4) increase the availability of confidential and secure use of AID systems for all consumer groups;
(5) Increase communication and cooperation
between stakeholder groups.
The AGA: Guidelines for Clinical Practice of Pharmacological Interventions in Obese Patients in Adults (2022)
guideline group made 9 recommendations
.
The group strongly recommends pharmacological therapy for overweight and obese adults (body mass index ≥ 30 kg/m 2, or ≥ 27 kg/m2 with weight-related complications) who do not have adequate lifestyle interventions.
The panel recommended the use of 2.
4 mg of semaglutide, 3.
0 mg of liraglutide, phentermine-topiramate sustained-release, and naltrexone-bupropion sustained-release (based on moderate-certainty evidence), as well as phentermine and diethylpropionic acid (based on low-certainty evidence) for the long-term management of
overweight and obesity.
The guideline group recommends against orlistat
.
For overweight and obese adults who do not respond adequately to lifestyle interventions alone, long-term pharmacotherapy is recommended, and a variety of effective and safe treatment options
are available.
What are the diagnostic criteria for major diseases? What are the preferred therapeutic drugs and regimens? What clinical signs and symptoms are prioritized for diagnosing a disease?
Open the clinical guideline module of the decision assistant App, and the dialogue with the major guidelines at home and abroad authoritative guidelines decision-making assistant "clinical guidelines
" module has 1 👇.
Scan the QR code below 2.
Download the Clinical Decision Assistant App
3 Open the Decision Assistant app and click the icon
4.
Search Guide
Download the app and read a great guide every day!
Download the Decision Assistant App and check it anytime, anywhere~Click "Read Original" for more dried medications
